Company Overview

Update
Founded:
2000
Headquarters:
Leuven
Funding:
$37.5M
Categories:
Biotechnology
Description:
TiGenix is a biomedical company focused on research and development of innovative local treatments for damaged and osteoarthritic joints.

Detailed Description

Update

TiGenix NV/SA (TiGenix) and its subsidiaries TiGenix Inc. and TC CEF LLC. is a Belgium-based biomedical company that focuses on innovative local treatments for damaged and osteoarthritic joints. The Company is exploiting the power of regenerative medicine for the development of durable treatments, validated through controlled clinical studies, for these indications. TiGenix is located in Leuven and was founded as a spin-off of the Catholic University of Leuven and the University of Ghent. TiGenix is developing a portfolio of products that addresses specific musculoskeletal problems. The lead indication among these is cartilage damage, which is a debilitating affliction severely affecting the mobility and functioning of patients. During the fiscal year ended December 31, 2009, the Company acquired Orthomimetics Ltd.

Current Team (7)

Update

Funding Rounds (3) - $37.5M

Update

Board Members and Advisors (2)

Update

Acquisitions (1)

Update
  • Cb default image

    Orthomimetics

    Orthomimetics develops bio-material products such as Chondromimetic, which is used in treating...
    Nov 30, 2011 -Stock

Investors (1)

Update

Offices/Locations (1)

Update
  • Office

    Haasrode Researchpark 1724

    Romeinse straat 12 bus 2

    Leuven, 3001

    BEL

Images (1)

Update
  • Bb21eaedb9f8025b0b0b541edb34c530